General Information of Drug (ID: DMR74OM)

Drug Name
Cypate-[(RGD)4-NH2]2 Drug Info
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
91936297
TTD Drug ID
DMR74OM

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Discontinued Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
XEMILOFIBAN DMBRYT8 Cardiovascular disease BA00-BE2Z Discontinued in Phase 3 [2]
DMP-802 DMDK6HP N. A. N. A. Discontinued in Phase 1 [3]
SC-47643 DMIE039 N. A. N. A. Terminated [4]
SB-223245 DM3JQCF N. A. N. A. Terminated [5]
L-709780 DMB3ZTI N. A. N. A. Terminated [6]
Ro-43-8857 DM4VY8S N. A. N. A. Terminated [3]
SKF-107260 DMM8F0V N. A. N. A. Terminated [7]
L-738167 DMO69X8 N. A. N. A. Terminated [3]
DMP-757 DMGNUXC N. A. N. A. Terminated [8]
Ro-43-5054 DMPNHF0 N. A. N. A. Terminated [3]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Integrin alpha-V (ITGAV)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Abituzumab DMTCXSG Colorectal cancer 2B91.Z Phase 2 [9]
IMGN-388 DMSYB83 Solid tumour/cancer 2A00-2F9Z Phase 1 [10]
SB-223245 DM3JQCF N. A. N. A. Terminated [5]
C(-GRGDfL-) DMTMJAI Discovery agent N.A. Investigative [11]
SB-265123 DM8UKH7 Discovery agent N.A. Investigative [12]
C(RGDfF) DMMBESU Discovery agent N.A. Investigative [13]
Ac-Asp-Arg-Leu-Asp-Ser-OH DMYHADT Discovery agent N.A. Investigative [14]
C[-Arg-Gly-Asp-Acpca21-] DMXCUDV Discovery agent N.A. Investigative [15]
C-[-Arg-Gly-Asp-Acpca32-] DMVM7B2 Discovery agent N.A. Investigative [15]
Cyclo-[-Arg-Gly-Asp-Amp22-] DMBELJK Discovery agent N.A. Investigative [16]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Integrin alpha-V (ITGAV) TTT1R2L ITAV_HUMAN Inhibitor [1]
ITGB3 messenger RNA (ITGB3 mRNA) TTJA1ZO ITB3_HUMAN Inhibitor [1]

References

1 Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75.
2 Potent, orally active GPIIb/IIIa antagonists containing a nipecotic acid subunit. Structure-activity studies leading to the discovery of RWJ-53308. J Med Chem. 1999 Dec 16;42(25):5254-65.
3 Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73.
4 Novel thiazole-based heterocycles as selective inhibitors of fibrinogen-mediated platelet aggregation. J Med Chem. 1995 Jan 6;38(1):34-41.
5 Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a resten... Bioorg Med Chem Lett. 1998 Nov 17;8(22):3171-6.
6 Non-peptide fibrinogen receptor antagonists. 3. design and discovery of a centrally constrained inhibitorc, Bioorg. Med. Chem. Lett. 4(15):1835-1840 (1994).
7 Preparation and Properties of a fibrinogen receptor antagonist containing the Arg-Gly-Asp sequence and nitroxide radicals, Bioorg. Med. Chem. Lett. 3(6):1179-1184 (1993).
8 Synthesis and antiplatelet activity of DMP 757 analogs, Bioorg. Med. Chem. Lett. 5(18):2097-2100 (1995).
9 Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. Ann Oncol. 2015 Jan;26(1):132-40.
10 Anti-alphav integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats. Cancer Res. 2010 Oct 1;70(19):7591-9.
11 Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem. 2007 Nov 29;50(24):5878-81.
12 1,2,3,4-Tetrahydroquinoline-containing alphaVbeta3 integrin antagonists with enhanced oral bioavailability. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5937-41.
13 Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
14 Synthesis and biological evaluation of non-peptide alpha(v)beta(3)/alpha(5)beta(1) integrin dual antagonists containing 5,6-dihydropyridin-2-one sc... Bioorg Med Chem. 2007 Dec 1;15(23):7380-90.
15 Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
16 Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82.